Expression Profile and Prognostic Values of CDH Family Members in Lung Adenocarcinoma

Dis Markers. 2022 Feb 11:2022:9644466. doi: 10.1155/2022/9644466. eCollection 2022.

Abstract

Many studies have confirmed that the classical cadherin (CDH) gene family may be involved in the development and progression of various tumors. However, the comprehensive assays of CDH family members in lung adenocarcinoma (LUAD) were rarely reported. In this study, our group analyzed TCGA datasets and identified 18 dysregulated CDH members in LUAD specimens. Several CDH members exhibited an increased level in LUAD specimens, such as CDH1, CDH2, CDH3, CDH4, CDH5, CDH15, CDH16, CDH17, CDH18, CDH24, and CDH26. However, some others exhibited decreased levels in LUAD specimens. Correlation analysis revealed that most CDH members were negatively regulated by the methylation of CDH genes, leading to their low expression in LUAD tissues. Survival assays identified 16 survival-related CDH members in LUAD patients. More importantly, we further performed multivariate analysis to determine the prognostic value of the above CDH family members and found that the expression levels of CDH17, CDH19, and CDH24 were an independent prognostic biomarker of the LUAD outcome. Finally, the results of functional enrichments revealed that CDH members participated in several tumor-related pathways. Collectively, our findings suggest that CDH Family members functioned as oncogenes or antioncogenes in LUAD and may be a potential biomarker for this malignancy.

Publication types

  • Retracted Publication

MeSH terms

  • Adenocarcinoma of Lung / genetics*
  • Biomarkers, Tumor / genetics*
  • Cadherins
  • Humans
  • Lung Neoplasms / genetics*
  • Prognosis*
  • Transcriptome*

Substances

  • Biomarkers, Tumor
  • CDH17 protein, human
  • CDH19 protein, human
  • CDH24 protein, human
  • Cadherins